PANews reported on December 17th that Matrixport analysis points out that although the previous decline in Bitcoin's market capitalization share led to a temporaryPANews reported on December 17th that Matrixport analysis points out that although the previous decline in Bitcoin's market capitalization share led to a temporary

Analysis: The altcoin rebound failed to continue, and Bitcoin's short-term momentum is weakening.

2025/12/17 15:12

PANews reported on December 17th that Matrixport analysis points out that although the previous decline in Bitcoin's market capitalization share led to a temporary rebound in altcoins, this rebound failed to sustain itself as the overall market capitalization of the crypto market weakened. Over the past year, altcoins have generally underperformed, with market preference remaining concentrated on Bitcoin. Currently, Bitcoin's short-term momentum is weakening, and risk appetite is recovering only to a limited extent; the altcoin market is likely to see structural differentiation.

At this stage, trading should focus more on top-tier assets with high liquidity and better trading depth, while strengthening risk control and position management. The market has gradually shifted from an environment that emphasizes "long-term holding + dollar-cost averaging" to one that stresses market timing and active trading.

Market Opportunity
Moonveil Logo
Moonveil Price(MORE)
$0.003882
$0.003882$0.003882
-3.72%
USD
Moonveil (MORE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.